50results about How to "Has antitumor effect" patented technology

The invention discloses application of genetically engineered bacterium VNP-20009-M of attenuated salmonella typhimurium in preparation of medicines for preventing and treating metastasized cancers. The genetically engineered bacterium VNP20009-M has a tumor targeting property on cancer cells, has a remarkable effect for inhibiting metastasis and growth of cancer cells, and can be used for preparing medicines for preventing and treating metastasized tumors.

The invention relates to the field of medicines, specifically to an integrin blocker which inhibits generation of tumor vasculature and has integrin endophilicity and binding capacity. The blocker is a polypeptide. The integrin blocker polypeptide can be used to treat solid tumor. The integrin blocker can be applied in the preparation of medicines for treating tumor. The sequence of the integrin blocker is Ala-Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys-Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro (the sequence contains two disulfide bonds and the pairing manner is 1-4 and 2-3). The invention is characterized in that the tumor origins from primary or secondary cancer and sarcoma of human head and neck, brain, thyroid, pancreas, lung, liver, oesophagus, stomach, mammary gland, kidney, gallbladder, colon or rectum, ovary, uterus, cervix, prostate, bladder and testis. According to the invention, treatment spectrum of the integrin blocker is greatly expanded, novel thinking and prospect are provided for drug development, and the integrin blocker polypeptide AP25 has substantial social value and market value.

The invention discloses a mixed type liquid cigarette and a manufacturing method and the application. The mixed type liquid cigarette is made of materials consisting of tobacco leaf and / or tobacco pole, angelica, radix codonopsitis, astragalus, steroid, schisandra, scutellaria barbata, rhizome imperatae, fritillaria thunbergii, cinnamon, costus root and jujube. When people have the mixted type liquid cigarette of the invention, the cigarette does not need to be burned and does not produce tar and other carcinogenic substances. The cigarette not only has the natural fragrance flavor but also excites nervus centralis, relieves organic fatigue and anxiety, improves the respiratory system situation( for example, relieving cough, eliminating phlegm and relieving asthma), strengthens the organic immunological competence, and has antineoplastic effects. Therefore, the mixed type liquid cigarette serves as health care cigarette or medical cigarette and is used for human body health care or treatment.

The invention relates to application of protosappanin B, in particular to application of a 0.2 to 2.4 percent protosappanin B solution in preparation of bladder cancer resistant perfusion fluid. For filling up the research blank of the protosappanin B at home and abroad, the invention provides new application of the protosappanin B. Human bladder cancer cell strains T24 or mouse bladder cancer cell strains BTT are inoculated to mouse bodies to form bladder cancer, and the mice are grouped and respectively subjected to experiments with injection water, mitomycin and the protosappanin B; experiment results show that the lives of the mice injected with the mitomycin and the protosappanin B are prolonged, the tumor weight is reduced, and a tumor inhibiting effect is achieved; and the protosappanin B has a remarkable bladder cancer inhibiting effect, and can be widely applied to preparation of the bladder cancer resistant perfusion fluid.

The invention relates to a medicine and food dual-purpose traditional Chinese medicine composition with anti-tumor activity and immunoregulation effect and application thereof. The composition comprises ganoderma lucidum extract and radix astragali extract in mass ratio of 1:0.5-3, wherein the ganoderma lucidum extract comprises the following effective medicinal ingredients in percentage by weight: 50-70% of ganoderma lucidum polysaccharides and 6-10% of ganoderma lucidum total triterpene; and the radix astragali extract comprises the effective medicinal ingredient in percentage by weight: 20-45% of radix astragali polysaccharide. Based on traditional Chinese medicine pharmacological animal experiments, the composition of the invention is found having anti-tumor effect, improves the immunocompetence of a body, and has a medicine and food dual-purpose property. In addition, compared with single ganoderma lucidum, the use of the radix astragali as raw material reduces the cost of the traditional Chinese medicine composition, the anti-tumor and immunoregulation curative effects are close to the curative effects of the same amount of the single ganoderma lucidum, and the invention has certain economic value.

The invention discloses an andrographolide derivative and a preparation method and application thereof. The derivative has a structure expressed by the formula (1), wherein R1 is C1 to C11 chain hydrocarbon or C1 to C11 chain hydrocarbon with terminals substituted by ternary to heptabasic ring groups; and R2 and R3 are hydrogen, organic acid radical, inorganic acid radical, alkyl or acryl. The andrographolide derivative can be made into tablets, capsules, granules, fine granules, powder, pills, patches, oral liquid or injection.

The invention relates to a construction method and applications of targeting oncolytic-adenovirus carier Ad-TD-gene. The carrier of the oncolytic-adenouirus is Ad5, the adenovirus-5 in Subcategory C;three internal genes of the adenovirus, including E1A-CR2, E1B19K and E3gp-19K, are deleted; an E3B gene is retained, and an E3gp-19K promoter expression exogenous therapeutic gene is retained; and any antigen gene which is helpful to treating tumors or used for infectious disease vaccines can be inserted into the carrier. The Ad-TD-gene has the advantages of specificity, high safety and high efficiency, can carry various antigen genes treating tumors, and can be used for treating various solid tumors. By utilizing the human chemotactic factor CCL 21 gene as the therapeutic gene, the Ad-TD-hccL21 has the effects of tumor targeting and tumor resistance, lays foundation for introducing targeting genetic engineering medicines towards clinical applications, and provides an effective therapy for patients with tumors.

The invention discloses a podophyllotoxin derivative I or pharmaceutically acceptable salt thereof. In the derivative, R1, R2 and R3 are independently selected from hydrogen, nitryl, halogen, trifluoromethyl and C1-C6 alkoxy. The invention also discloses a method for preparing the podophyllotoxin derivative I, which comprises the step of performing a condensation reaction between a compound II and a compound III in a solvent under the action of a condensing agent and alkali. The invention also discloses application of the podophyllotoxin derivative I or pharmaceutically acceptable salt thereof in the aspect of preparation of anti-tumor medicaments. The podophyllotoxin derivative I is a novel compound with anti-tumor activity, provides a new research direction for research and development of anti-cancer medicaments, and expands the research range of podophyllotoxin derivative anti-cancer medicaments.

The invention discloses a method for preparing an anti-bacterial and anti-cancer titanium dioxide nanotube from an iridium complex. The method comprises steps as follows: 1), the iridium complex is acquired; 2), the iridium complex is dissolved in ethyl alcohol; 3), the titanium dioxide nanotube is soaked in an iridium complex solution, nitrogen is introduced and microwave processing is performed; 3), the solution is left to stand and cooled to the normal temperature, then the solution is pressurized to 20-25 Mpa, keeps the pressure for 2-3 min and then is depressurized to normal pressure, and centrifugation is performed for 30-60 min; 4), a liquid supernatant after centrifugation is removed, a lower solution and solids are taken and placed in an environment at the temperature of 100-120 DEG C, are pressurized to 20-25 Mpa, keep the pressure for 2-3 min and then are depressurized to the normal pressure, and drying is performed for 20-26 h. With the adoption of the method, anti-bacterial and anti-cancer capacity of the titanium dioxide nanotube is high, growth of harmful cells can be persistently and effectively inhibited, the titanium dioxide nanotube particularly has more remarkable resisting effect on bone cancer, and the medical utilization effect of the titanium dioxide nanotube can be effectively improved.

The invention relates to recovery aid granules containing hoantchy root and semen coicis. A preparation method comprises the following steps: taking 10 gouts of raw materials such as hoantchy root, ginseng, semen coicis, tuckahoe, Actinidia valvata Dunn, barbed skullcap herb, paris rhizome, oldenlandia diffusa, licorice and Chinese jujube according to a definite proportion; then crushing the semen coicis from the 10 gouts of the raw materials into meal, adding petroleum ether into the meal by 1 to 3 times (in terms of weight proportion) of the amount of the semen coicis, heating and reflowing the mixture for 0.8 to 1.2 hours at a temperature of between 60 and 90 DEG C, filtering the mixture twice, mixing the extracts, and reclaiming the petroleum ether to obtain semen coicis oil; after the extraction, adding 8 to 12 times of water into the semen coicis and the rest nine gouts of the raw materials, stirring and boiling the mixture for 0.8 to 1.2 hours, filtering the extract, and condensing the extract to have a relative density of 1.15 to 1.22 g / cm; and adding the semen coicis oil and stevioside into the condensed extract, evenly mixing the mixture, spraying and drying the mixture, adding dextrin into the solid, and drying the mixture to prepare the granules. The recovery aid granules are prepared by refining, extracting and scientifically processing the pure traditional Chinese medicine, and have the efficacies of eliminating pathogens and strengthening healthy energy, tonifying qi and nourishing the blood.

The present invention belongs to the field of medicine, and specifically relates to a new borneol use and a lung cancer treatment drug composition. The first technical problem solved by the present invention is a use of borneol in anticancer drug preparation. The second technical problem solved by the present invention is to provide a completely new lung cancer treatment drug composition, which comprises borneol and cyclophosphamide. Test results show that single use of the borneol provides a lung cancer inhibition effect, combination of the borneol and the cyclophosphamide provides an increased tumor inhibition rate, and improvement of leukocyte inhibition by the cyclophosphamide is further provided. With the present invention, a completely new, safe and efficient selection is provided for clinical lung cancer treatment.

The invention discloses a low-toxicity Pt complex, and belongs to the technical field of anticancer chemical drugs. The structure of the complex is as shown in a general formula (1) or a general formula (2), pterostilbene is introduced into the platinum (IV) complex, and the anti-tumor effect of the platinum complex is improved and the toxic and side effects of the platinum complex on normal cells are reduced by utilizing the anti-inflammatory and anti-oxidation double functions of the pterostilbene.

The invention belongs to the fields of medicinal chemistry and pharmacotherapeutics, and discloses a quinolone derivative as shown in a formula I in the description or pharmaceutically acceptable salt or ester thereof. The invention also discloses application of the quinolone derivative or the pharmaceutically acceptable salt or ester thereof in preparation of an STAT3 inhibitor or in preparation of a medicine for preventing and / or treating tumor-related diseases. Pharmacological experiments prove that the quinolone derivative or the pharmaceutically acceptable salt or ester thereof can achieve the anti-tumor purpose by inhibiting proliferation of tumor cells and inducing apoptosis of the tumor cells, and the quinolone derivative or the pharmaceutically acceptable salt or ester thereof has an anti-tumor effect and is relatively low in toxicity. The quinolone derivative can be combined with a target protein STAT3SH2 structural domain, so that formation of an STAT3 homodimer is mediated, and a JAK-STAT3 cellular pathway is selectively inhibited.

The invention relates to application of an ophicalcitum extract and a method for preparing the same, and discloses a method for preparing ophicalcitum (with serpentine serving as a main component) extracting solution and anticancer application thereof. The extract can be extracted from ophicalcitum, and serpentine simple ore, serpentine-containing marble and rock having the characteristic of a serpentine ore family. The extract is originated from an ophicalcitum medicinal material, medicinal material submicron powder, mineral suspended particles and ophicalcitum natural nano-fiber thereof (the origins comprise raw / forged products). Researches on in-vivo and in-vitro pharmacological activities indicate that the ophicalcitum extract has very high anticancer activity and is expected to be developed into a new anticancer medicament using the ophicalcitum extract as a raw material and having wide clinical use value and commercial development value.

The invention relates to an miR-21 small molecule inhibitor and an application The medicament of the invention can specifically inhibiting the expression of miR-21, thereby promoting a compound 2,4-diamino-1,3-diazacyclohexane-5-nitrile which can induce various tumor cell apoptosis. The binding capability of 2,4-diamino-1,3-diazacyclohexane-5-nitrile is that: Ki=1.49nM, deltaG=-12.04kcal / mol. The preparation method comprises: dissolving 2,4-diamino-1,3-diazacyclohexane-5-nitrile in deionized water to prepare mother solution, adding the mother solution into a tumor cell (colloid tumor, stomach cancer and breast cancer) culturing system according to a certain proportion. The medicament can specifically inhibit the expression of miR-21 without affecting the expression of miRNA. The cell cycle appearances G0 / G1 phase arrest, the cell apoptosis proportion is obviously increased, and more effective inhibition to tumour can be implemented.

The invention discloses a fusion protein of PA4-Fc and a coding gene and application thereof. The protein provided by the invention is any one of 1) a protein formed by amino acid residue sequences of a sequence 2 in a sequence table and 2) a protein which is derived from 1), is obtained by subjecting the amino acid residue sequences of the sequence 2 in the sequence table to substitution and / or deletion and / or addition of one or more amino acid residues and has the same functions. Experiments prove that a DNA sequence expressing the fusion protein PA4-Fc is constructed by optimizing codons and is imported into cells via carriers to express and purify the fusion protein PA4-Fc; the fusion protein can suppress growth of tumor cells and has an antitumor effect; besides, as the fusion protein contains a human IgG1Fc fragment, the half-life period of the fusion protein in bodies can be lengthened.

The invention provides a drug for inhibiting brain tumor and application thereof. The drug for inhibiting the brain tumor comprises at least one TRPV4 agonist capable of promoting calcium ion internalflow of a TRPV4 signal channel. The drug has a good treatment effect on brain tumors and related diseases thereof, and has a good application prospect in treatment of brain tumors and related diseases thereof. The drug is applied to medicines for treating brain tumors and related diseases thereof, can reduce toxic and side effects generated in the clinical treatment process of the brain tumors and the related diseases thereof and improve the treatment effect of the brain tumors and the related diseases thereof.

The invention provides a camptothecin prodrug based on cationic amino acid modification, a preparation method thereof, nano drug-loaded particles and an application thereof. The camptothecin prodrug has the structure of formula I, formula II, formula III, formula IV or formula V; the prodrug of camptothecin with the above structure is a water-soluble chemotherapeutic agent, and has excellent stability. Camptothecin has anticancer activity similar to that of camptothecin itself. The prodrug of camptothecin has a positive charge and can be electrostatically combined with a negatively charged polymer in situ to obtain nano-drug-loaded particles with uniform nano-particle size and small particle size, and has high drug-loading capacity. The drug-loaded nanoparticles have good killing effect onMCF7, CT26, 4T1, HeLa, A549 and other tumor cells. After storage in PBS for 2 days, the lactone ring will not change into carboxylate form and lose its pharmacodynamics. The particle size of drug-loaded nanoparticles ranged from 45 nm to 55 nm. The drug loading of nanoparticles is 23 - 48.5%.

The invention discloses a preparation method and application of a tsinling larkspur root extractive. The preparation method comprises the following steps of: (1) weighing crushed tsinling larkspur root, adding 95% of ethanol, and dipping for 0.5 hour; (2) carrying out reflux extraction for 3 hours at 60 DEG C in three times by a soxhlet extractor, and repeating the step three times; and (3) concentrating the extracting solution obtained in step (2) by a rotary evaporator until the extracting solution is nearly dry, so as to obtain the extractive, and then dissolving by DMSO (Dimethylsulfoxide). The preparation method of the tsinling larkspur root extractive is simple; and the tsinling larkspur root extractive is low in price and has a certain antineoplastic effect, so that the tsinling larkspur root extractive has a great application value for preparation of antineoplastic drugs.

The invention relates to a visual fucoidin embolization microsphere and a preparation method thereof, and belongs to the field of embolization microspheres. The embolization microsphere adopts fucoidin as a main component, and the fucoidin is functionally modified, so that the embolization microsphere has a magnetic resonance imaging function. The embolization agent is low in cost and can replace existing expensive embolization microsphere products at home and abroad.

The invention belongs to the field of preparation of antibody coupled medicines, and particularly relates to a coupled compound of an anti-5T4 antibody and a maytansine derivative DM4, a preparation method and an application. The coupled compound of the anti-5T4 antibody and the maytansine derivative DM4 is characterized by comprising the anti-5T4 antibody, the maytansine derivative DM4, and a joint molecule coupling the antibody and the maytansine derivative DM4, wherein one terminal of the joint molecule coupling the antibody and the maytansine derivative DM4 is coupled with amino of the anti-5T4 antibody via succinimide activated carboxylic ester; and the other terminal of the joint molecule forms a disulfide bond to be coupled with sulfydryl of the DM4. The antibody coupled compound reserves high affinity of the anti-5T4 antibody in target binding with 5T4, and high-efficiency cell killing ability of the maytansine derivative DM4; a medication effect is improved; toxic and side effects of a medicine on an organism are reduced at the same time; and the coupled compound can be used for preparing a medicine for tumor diagnosis and treatment and has good application prospects.

The invention relates to a method for improving the quality of animal semen by using chestnut flower water extract. After weaning male mammals, the chestnut flower water extract is supplemented by gavage or added to feed every day, and the intake dose of small male mammals is 0.01-20mg / kg body weight, the ingestion dose of medium-sized male mammals is 0.1-20mg / kg feed, the chestnut flower water extract is a freeze-dried powder obtained by ultra-microfiltration after ultrasonic extraction. The present invention proposes for the first time that the water extract of chestnut flower is extracted by ultrasonic waves, and after further ultrafine filtration, supplementary feeding to male mammals can significantly improve the semen quality of animals, and the timing of supplementary feeding is immediately after weaning of male mammals. The scheme enables male mammals to better establish a reproductive system, fully taps the genetic potential of male animals, and expands the range of utilization of chestnut flower water extract.

The invention belongs to the technical field of medicines, and in particular relates to a camptothecin glycoconjugate and its preparation method and application. The invention provides a camptothecin glycoconjugate, and the camptothecin glycoconjugate is synthesized by linking camptothecin and hexose with adipic acid as a linker. Experimental results show that the camptothecin glycoconjugate has an anti-tumor effect, and has high efficiency and low toxicity compared with camptothecin. GLUT1 is widely distributed on the blood-brain barrier and red blood cells. The experimental results show that the camptothecin glycoconjugates of the present invention can be recognized and transported by GLUT1, and enter into tumor cells through the GLUT1 pathway to achieve anti-tumor effects. Moreover, the camptothecin glycoconjugates of the present invention Glycoconjugates, as a cytotoxic quinoline alkaloid, can inhibit DNA topoisomerase (TOPO I).

The invention belongs to the technical field of medicine, and particularly relates to camptothecin glycoconjugate and a preparation method and application thereof. According to the camptothecin glycoconjugate, the camptothecin glycoconjugate is synthesized and obtained by connecting camptothecin and hexose with adipic acid as spacer. The experimental results show that the camptothecin glycoconjugate has anti-tumor effect, and has the effect of high efficiency and low toxicity compared with the camptothecin. GLUT1 is widely distributed on a blood-brain barrier and red blood cells. The experimental results show that the camptothecin glycoconjugate can be recognized and transported by the GLUT1, and the anti-tumor effect can be achieved by entering tumor cells through a GLUT1 pathway. As a kind of cytotoxicity quinoline alkaloid, the camptothecin glycoconjugate can inhibit DNA topoisomerase (TOPO I).

The invention discloses a fusion protein of PA4-Fc and a coding gene and application thereof. The protein provided by the invention is any one of 1) a protein formed by amino acid residue sequences of a sequence 2 in a sequence table and 2) a protein which is derived from 1), is obtained by subjecting the amino acid residue sequences of the sequence 2 in the sequence table to substitution and / or deletion and / or addition of one or more amino acid residues and has the same functions. Experiments prove that a DNA sequence expressing the fusion protein PA4-Fc is constructed by optimizing codons and is imported into cells via carriers to express and purify the fusion protein PA4-Fc; the fusion protein can suppress growth of tumor cells and has an antitumor effect; besides, as the fusion protein contains a human IgG1Fc fragment, the half-life period of the fusion protein in bodies can be lengthened.

The invention relates to the field of yoghourt processing, in particular to functional yoghourt with long shelf life and a preparation method thereof. The preparation method of the functional yoghourt with long shelf life according to the invention comprises the following steps of: (1) uniformly mixing raw materials, degassing, homogenizing and sterilizing; (2) adding fermentation species, fermenting, filling, and performing post maturation to obtain a finished product; (3) and performing radiation sterilization on the finished product obtained in the step (2) with the radiation dose between 3 kGy and 6 kGy to obtain the functional yoghourt with long shelf life, wherein the fermentation species in the step (2) comprise bifidobacterium infantis. Radiation sterilization is performed with the radiation dose between 3 kGy and 6 kGy, so that the shelf life of the yoghourt can be prolonged; meanwhile, the bifidobacterium infantis is added into the yoghourt, so that the product is endowed with an antitumor function. The yoghourt prepared by using the method has good tissue state, mouthfeel and flavor, does not undergo great changes in the aspects of color, mouthfeel, flavor and tissue within the storage time of six months, and has high stability.

The invention discloses a compound preparation for treating liver cancer. The compound preparation is characterized by being prepared from the following raw material medicines in parts by weight: 9-15 parts of radix pseudostellariae, 9-15 parts of roasted rhizoma atractylodis macrocephalae, 9-15 parts of poria, 3-6 parts of pericarpium citri reticulatae, 6-12 parts of radix glehniae, 6-12 parts of radix asparagi, 12-30 parts of raw radix astragali, 6-12 parts of radix angelicae sinensis, 3-6 parts of house lizard, 6-12 parts of rhizoma arisaematis, 6-12 parts of curcuma zedoary, 12-30 parts of herba selaginellae doederleinii and 12-30 parts of cottonrose hibiscus leaves. The compound preparation can be prepared into tablets, granules, capsules or oral liquid by adopting a conventional method. Pharmacodynamics shows that the compound preparation has the effects of improving general conditions of liver cancer patients and inhibiting tumor growth, metastasis and relapse independently or in combination with other liver cancer targeted drugs or chemotherapeutic drugs.

The invention relates to application of an ophicalcitum extract and a method for preparing the same, and discloses a method for preparing ophicalcitum (with serpentine serving as a main component) extracting solution and anticancer application thereof. The extract can be extracted from ophicalcitum, and serpentine simple ore, serpentine-containing marble and rock having the characteristic of a serpentine ore family. The extract is originated from an ophicalcitum medicinal material, medicinal material submicron powder, mineral suspended particles and ophicalcitum natural nano-fiber thereof (the origins comprise raw / forged products). Researches on in-vivo and in-vitro pharmacological activities indicate that the ophicalcitum extract has very high anticancer activity and is expected to be developed into a new anticancer medicament using the ophicalcitum extract as a raw material and having wide clinical use value and commercial development value.

The invention belongs to the field of the traditional Chinese medicine and discloses a gynostemma pentaphylla flavonoid compound, a preparation and an application thereof in an antitumor drug. The method comprises the following steps: (1) extracting the rough gynostemma pentaphylla powder by adopting an alcohol solution for heating and refluxing, centrifuging and concentrating, thereby acquiring gynostemma pentaphylla ethyl alcohol extract; (2) using water for dissolving the extract, filtering, adopting petroleum ether for extracting the filtrate and adopting ethyl acetate for extracting lower-layer water phase; (3) performing vacuum concentration on the ethyl acetate phase, drying and adopting a chloroform-methyl alcohol mixed solvent for isocratic elution in a silica gel column, therebyacquiring multiple fractions; (4) pouring the fractions onto a gel column, eluting with methyl alcohol and collecting the fractions with equal analogous values; (5) pouring the fractions onto a ODS column, using methyl alcohol-water for isocratic elution, collecting the fractions and drying, thereby acquiring the gynostemma pentaphylla flavonoid compound. The gynostemma pentaphylla flavonoid compound prepared according to the invention has the advantages of high anti-tumor activity, low dosage and no toxic or side effect to normal human hepatic cells in same dosage.